Arbutus Biopharma Corp Net Assets
Arbutus Biopharma Corp net assets. Based on the latest financial reports, Arbutus Biopharma Corp (ABUS) has net assets worth $258.73 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($274.02 Million) and total liabilities ($15.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See ABUS equity financing ratio to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $258.73 Million |
| % of Total Assets | 94.42% |
| Annual Growth Rate | 6.38% |
| 5-Year Change | -54.81% |
| 10-Year Change | -62.28% |
| Growth Volatility | 2291.47 |
Net Assets of Arbutus Biopharma Corp (1998–2025)
Net assets of Arbutus Biopharma Corp from 1998 to 2025. This chart illustrates how Arbutus Biopharma Corp's net assets have evolved over time, based on quarterly financial data. Also explore Arbutus Biopharma Corp annual equity growth to track the company's year-over-year net asset growth rate.
Annual Net Assets for Arbutus Biopharma Corp (1998–2025)
The table below shows the annual net assets of Arbutus Biopharma Corp from 1998 to 2025. For live market cap and overall valuation, see ABUS market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $76.58 Million | -21.35% |
| 2024-12-31 | $97.37 Million | -8.16% |
| 2023-12-31 | $106.02 Million | -22.53% |
| 2022-12-31 | $136.85 Million | -19.23% |
| 2021-12-31 | $169.44 Million | +66.17% |
| 2020-12-31 | $101.97 Million | +40.17% |
| 2019-12-31 | $72.74 Million | -63.67% |
| 2018-12-31 | $200.23 Million | +9.72% |
| 2017-12-31 | $182.50 Million | -10.10% |
| 2016-12-31 | $203.00 Million | -62.93% |
| 2015-12-31 | $547.68 Million | +522.36% |
| 2014-12-31 | $88.00 Million | +48.67% |
| 2013-12-31 | $59.19 Million | +44.65% |
| 2012-12-31 | $40.92 Million | +686.08% |
| 2011-12-31 | $5.21 Million | -51.49% |
| 2010-12-31 | $10.73 Million | -69.72% |
| 2009-12-31 | $35.44 Million | -7.45% |
| 2008-12-31 | $38.29 Million | +108.43% |
| 2007-12-31 | $18.37 Million | +11711.55% |
| 2006-12-31 | $155.53K | +100.84% |
| 2005-12-31 | $-18.49 Million | -76.18% |
| 2004-12-31 | $-10.50 Million | -124.20% |
| 2003-12-31 | $43.38 Million | -4.34% |
| 2002-12-31 | $45.35 Million | -26.25% |
| 2001-12-31 | $61.49 Million | +104.76% |
| 2000-12-31 | $30.03 Million | +11.72% |
| 1999-12-31 | $26.88 Million | +86.28% |
| 1998-12-31 | $14.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arbutus Biopharma Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 135952588035.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Arbutus Biopharma Corp Net Assets Breakdown (December 2025)
Arbutus Biopharma Corp net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.42 Billion | 1856.23% |
| Other Comprehensive Income | $-48.10 Million | -62.81% |
| Other Components | $83.32 Million | 108.80% |
| Total Equity | $76.58 Million | 100.00% |
Arbutus Biopharma Corp Competitors by Market Cap
The table below lists competitors of Arbutus Biopharma Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Synsam AB
ST:SYNSAM
|
$847.90 Million |
|
Orient Semiconductor Electronics Ltd
TW:2329
|
$848.07 Million |
|
Shenzhen United Winners Laser Co Ltd
SHG:688518
|
$848.09 Million |
|
Nufarm Ltd
AU:NUF
|
$848.29 Million |
|
TrustCo Bank Corp NY
NASDAQ:TRST
|
$847.70 Million |
|
Ningbo Construction Co Ltd
SHG:601789
|
$847.65 Million |
|
Jiangsu Yinhe Electronics Co Ltd
SHE:002519
|
$847.24 Million |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
$847.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arbutus Biopharma Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 97,366,000 to 76,576,000, a change of -20,790,000 (-21.4%).
- Net loss of 33,501,000 reduced equity.
- Other comprehensive income increased equity by 37,000.
- Other factors increased equity by 12,674,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.50 Million | -43.75% |
| Other Comprehensive Income | $37.00K | +0.05% |
| Other Changes | $12.67 Million | +16.55% |
| Total Change | $- | -21.35% |
Book Value vs Market Value Analysis
This analysis compares Arbutus Biopharma Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.64x to 10.71x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $6.67 | $4.28 | x |
| 1999-12-31 | $9.54 | $4.28 | x |
| 2000-12-31 | $6.09 | $4.28 | x |
| 2001-12-31 | $12.13 | $4.28 | x |
| 2002-12-31 | $6.90 | $4.28 | x |
| 2003-12-31 | $6.09 | $4.28 | x |
| 2004-12-31 | $-1.36 | $4.28 | x |
| 2005-12-31 | $-2.40 | $4.28 | x |
| 2006-12-31 | $0.04 | $4.28 | x |
| 2007-12-31 | $3.85 | $4.28 | x |
| 2008-12-31 | $4.72 | $4.28 | x |
| 2009-12-31 | $3.43 | $4.28 | x |
| 2010-12-31 | $1.04 | $4.28 | x |
| 2011-12-31 | $0.46 | $4.28 | x |
| 2012-12-31 | $2.86 | $4.28 | x |
| 2013-12-31 | $3.87 | $4.28 | x |
| 2014-12-31 | $3.92 | $4.28 | x |
| 2015-12-31 | $12.05 | $4.28 | x |
| 2016-12-31 | $3.83 | $4.28 | x |
| 2017-12-31 | $3.33 | $4.28 | x |
| 2018-12-31 | $3.62 | $4.28 | x |
| 2019-12-31 | $1.27 | $4.28 | x |
| 2020-12-31 | $1.34 | $4.28 | x |
| 2021-12-31 | $1.59 | $4.28 | x |
| 2022-12-31 | $0.91 | $4.28 | x |
| 2023-12-31 | $0.64 | $4.28 | x |
| 2024-12-31 | $0.52 | $4.28 | x |
| 2025-12-31 | $0.40 | $4.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arbutus Biopharma Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -237.88%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.24x
- Recent ROE (-43.75%) is below the historical average (362.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -60.67% | -713.22% | 0.08x | 1.10x | $-10.20 Million |
| 1999 | -30.41% | -716.68% | 0.04x | 1.07x | $-10.86 Million |
| 2000 | -30.65% | -520.56% | 0.05x | 1.08x | $-12.21 Million |
| 2001 | -22.79% | -405.13% | 0.05x | 1.10x | $-20.16 Million |
| 2002 | -59.09% | -528.27% | 0.10x | 1.17x | $-31.33 Million |
| 2003 | -78.55% | -1247.26% | 0.05x | 1.17x | $-38.41 Million |
| 2004 | 0.00% | -230.49% | 0.30x | 0.00x | $-27.00 Million |
| 2005 | 0.00% | -60.64% | 0.72x | 0.00x | $-6.21 Million |
| 2006 | 11625.33% | 132.90% | 2.25x | 38.80x | $18.06 Million |
| 2007 | -14.06% | -16.22% | 0.64x | 1.35x | $-4.42 Million |
| 2008 | -30.60% | -121.56% | 0.23x | 1.11x | $-15.55 Million |
| 2009 | -26.32% | -67.68% | 0.33x | 1.18x | $-12.87 Million |
| 2010 | -115.68% | -58.14% | 1.02x | 1.96x | $-13.49 Million |
| 2011 | -186.95% | -59.69% | 1.19x | 2.63x | $-10.25 Million |
| 2012 | 73.18% | 211.19% | 0.27x | 1.29x | $25.86 Million |
| 2013 | -23.76% | -90.95% | 0.22x | 1.21x | $-19.98 Million |
| 2014 | -44.09% | -258.67% | 0.13x | 1.34x | $-47.60 Million |
| 2015 | -11.16% | -245.73% | 0.03x | 1.30x | $-115.89 Million |
| 2016 | -189.21% | -25606.67% | 0.01x | 1.36x | $-404.40 Million |
| 2017 | -46.25% | -788.79% | 0.05x | 1.30x | $-102.65 Million |
| 2018 | -28.52% | -967.80% | 0.03x | 1.14x | $-77.12 Million |
| 2019 | -211.32% | -2557.36% | 0.06x | 1.45x | $-161.00 Million |
| 2020 | -62.52% | -921.97% | 0.05x | 1.34x | $-73.94 Million |
| 2021 | -45.00% | -693.91% | 0.05x | 1.21x | $-93.19 Million |
| 2022 | -50.75% | -178.01% | 0.20x | 1.43x | $-83.14 Million |
| 2023 | -68.71% | -401.57% | 0.13x | 1.36x | $-83.45 Million |
| 2024 | -71.81% | -1133.04% | 0.05x | 1.35x | $-79.66 Million |
| 2025 | -43.75% | -237.88% | 0.15x | 1.24x | $-41.16 Million |
Industry Comparison
This section compares Arbutus Biopharma Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $48,332,386
- Average return on equity (ROE) among peers: -34.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $258.73 Million | -60.67% | 0.06x | $847.89 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $31.35 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $99.10 Million | -22.07% | 0.12x | $260.76 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $27.72 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.58 Billion |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more